Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Centrophenoxine (also known as meclofenoxate) is a compound developed in the 1950s and has been investigated primarily for its potential nootropic and neuroprotective effects, particularly in the context of age-related cognitive decline and dementia, including Alzheimer’s disease. Preclinical studies suggest that centrophenoxine may reduce lipofuscin accumulation in neuronal cells, enhance membrane phospholipid metabolism, and increase cerebral glucose uptake. These effects could, in theory, counter some neurodegenerative processes associated with dementia.

Several small clinical studies, mostly conducted in Eastern Europe and Russia from the 1960s-1980s, have reported modest improvements in cognitive function, memory, and overall clinical state in elderly patients with senile dementia or Alzheimer's disease. However, these studies often suffered from methodological limitations such as small sample sizes, lack of rigorous controls, and inadequate blinding. Modern, large-scale randomized controlled trials are lacking.

Major clinical guidelines and systematic reviews do not currently endorse centrophenoxine as a standard treatment for dementia due to insufficient high-quality evidence. Nonetheless, its mechanism of action and some positive findings from early trials continue to justify ongoing scientific interest and research into its potential therapeutic roles in neurodegenerative diseases.

More about Centrophenoxine
More about Dementia

Other ingredients used for Dementia

Other health conditions supported by Centrophenoxine

Products containing Centrophenoxine